Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain
- Conditions
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT01001923
- Locations
- 🇺🇸
Sanofi-Aventis Investigational Site Number 840043, Dallas, Texas, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840003, Monterey, California, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840052, Winston Salem, North Carolina, United States
A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 159
- Registration Number
- NCT00991172
- Locations
- 🇺🇸
Regeneron Investigational Site, San Antonio, Texas, United States
🇺🇸Regeneron Invesitgational Site, West Jordan, Utah, United States
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 323
- Registration Number
- NCT00964795
PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 248
- Registration Number
- NCT00958438
A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00944892
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
- Conditions
- Interventions
- First Posted Date
- 2009-07-21
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 189
- Registration Number
- NCT00943072
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 83
- Registration Number
- NCT00871559
A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2012-05-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT00856310
Study Utilizing Rilonacept in Gout Exacerbations
- Conditions
- Interventions
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT00855920
Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1315
- Registration Number
- NCT00856206